Open AccessP553: A PHASE 2, OPEN‐LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST‐LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA
Author(s) -
Vyas P.,
Daver N. G.,
Chao M. P.,
Xing G.,
Renard C.,
Ramsingh G.,
Wei A. H.,
Sallman D. A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845100.10588.44
Subject(s) - medicine , tolerability , oncology , cohort , myeloid leukemia , phases of clinical research , minimal residual disease , azacitidine , hypomethylating agent , refractory (planetary science) , leukemia , chemotherapy , adverse effect , biochemistry , gene expression , dna methylation , gene , chemistry , physics , astrobiology